(Pink Sheets: BDGW), (Nasdaq: QTWW), (NASDAQ: PANC), (OTCBB:SRLM).

Turning Pennies into dollars: (Pink Sheets: BDGW), (Nasdaq: QTWW), (NASDAQ: PANC), (OTCBB:SRLM).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://bdgw.realpennies.com

Budget Waste Inc. (Pink Sheets: BDGW) (March 3rd, 2008) announced Monday that the company is on track to realize a 55% increase in revenues over the previous year.

BWI is pleased to announce that a projected increase in revenues of 55% should be reached for the current year ending March 31, 2008. BWI has generated an average monthly income of $1,350,000 for the first 9 months of 2007, this calculates into year end revenue of approximately $16,200,000. This represents an increase of approximately $5,759,000 over the previous year's income of $10,441,000.

Budget Waste Inc. is a waste solutions company in Western Canada providing complete waste and recycling services to commercial, industrial, construction, homebuilding, oilfield and residential clients. With our broad range of innovative services we offer our customers more value for their dollar and reduce accounting costs by providing streamlined billing. BWI is currently following its growth through acquisition strategy with exceptional success. With regulations throughout North America pressing companies and individuals to be more vigilant in the way they handle their waste products we see vast opportunity for expansion of our distinctive services. We are confidant that extraordinary growth and focus on customer needs will bring our stockholders outstanding value for the confidence they have placed in BWI.

For more info: http://qtww.realpennies.com

Quantum Fuel Systems Technologies Worldwide, Inc. (Nasdaq: QTWW) (March 5, 2008,) announced that its German solar partner, Asola Advanced and Automotive Solar Systems GmbH, has been awarded a contract by AS Solar GmbH for the supply of high-efficiency silicon photovoltaic solar modules. The value of this contract is estimated at $135 million over a three year period, beginning in 2008, and subject to final negotiations on quantity and price in 2009 and 2010.

Asola will supply its state-of-the-art 270 Watt and 230 Watt modules to AS Solar for installations primarily in Spain. AS Solar is a leading German integrated solar energy systems company with a strategic focus on Germany, Italy, and Spain.

"Asola is pleased to be selected by AS Solar to be its long-term supplier supporting their growing portfolio of European projects," said Asola's founder and CEO, Reinhard Wecker. "Our state-of-the-art, high-efficiency modules and high-quality module production processes were key to meeting all of AS Solar's rigorous requirements for these projects."

Quantum has recently announced acquisition of a 25% stake in Asola, and also a long-term supply contract with Ersol Solar Energy AG for the procurement of 155 MW of high-efficiency silicon photovoltaic solar cells, starting in 2008. The Ersol agreement guarantees a supply of solar cells to Quantum and Asola, thereby avoiding any potential future disruptions due to polysilicon shortages, as have been recently experienced by the solar cell industry. Resulting sales from the supply agreement with Ersol are anticipated to generate US $500 million for Asola and Quantum.

"We are excited to be able to announce this contract award for Asola's solar modules so soon after entering into the recently announced long-term photovoltaic cell purchase agreement," said Alan P. Niedzwiecki, President and CEO of Quantum. "Demand for Asola's high-quality solar modules continues to grow in the expanding renewable energy markets in Germany, Spain, Italy, and France. With our supply of solar cells secured, we believe that Quantum and Asola are well-positioned to meet this demand in Europe as well as to capitalize on the opportunities in California and the rest of North America."

The Spanish solar energy market is projected to grow in excess of 67% per year. Both Alan Niedzwiecki and Reinhard Wecker presented Quantum's and Asola's clean energy solutions at 'Genera08' Energy and Environment International Trade-fair in Madrid, Spain, 26-28th of February, 2008.

For more info: http://panc.realpennies.com

Panacos Pharmaceuticals, Inc. (NASDAQ: PANC) (March 4th, 2008) a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, announced that it has discovered factors that predict response to bevirimat, its lead HIV maturation inhibitor. In addition, it has completed a Phase 2b study (Study 203) of five treatment-experienced patient cohorts with doses ranging up to 400 mg daily and provided preliminary analysis of the combined study results. Patients who had the predictors of response and effective bevirimat target blood levels had a mean viral load reduction of 1.26 log10. The active dose range and plasma concentrations required for optimal response to bevirimat have been determined and are achievable using existing solid or liquid formulations. Clinically, bevirimat's adverse event profile was indistinguishable from placebo across all doses in the study.

"In a very short period of time we have made a number of significant discoveries with regard to bevirimat," said Dr. Alan W. Dunton, Panacos' President and CEO. "We can specifically target the patients who will respond well to bevirimat in advance. In that population, we have seen a dramatic treatment response: a greater mean viral load reduction than in any other HIV drug with a published functional monotherapy study. The favorable safety profile of bevirimat also suggests its potential utility in earlier treatment lines."

The predictors of response to bevirimat were found to be specific changes to less than 1% of the amino acids on the approximately 500 position HIV Gag protein, the target for bevirimat. Patients whose virus lacks these changes were much more likely to respond to bevirimat. These specific changes in Gag, known as polymorphisms, are easily determined by a simple addition to the rapid, inexpensive genotype tests already being routinely performed by practicing HIV physicians throughout the course of a patient's treatment. In general, HIV patients may have an increasing number of polymorphic viruses as their disease progresses. Analysis of a Panacos database of more than 100 HIV patients, most with advanced disease and heavy treatment experience, indicates that more than 50% of these patients would be suitable for bevirimat treatment. A preliminary analysis of a large academic North American patient database suggests that the proportion of treatment-nave patients who would respond to bevirimat may be much higher. Additional large patient databases are being utilized to generate even more accurate assessments of the prevalence of these specific Gag polymorphisms.

The mean viral load reduction across all 44 patients given bevirimat-regardless of their blood level-was 0.60 log10. In the group of patients that lacked Gag polymorphisms and had effective bevirimat target blood levels, more than 90% responded to bevirimat with a mean viral load reduction of 1.26 log10.

Analysis of the pharmacokinetic data from this study and other bevirimat clinical studies has revealed the bevirimat target blood levels, or threshold, above which patients are likely to respond if they lack the key Gag polymorphisms. This threshold concentration was achieved in all patients in the 203 study at liquid doses from 250 mg to 400 mg.

Table: Study 203 Week 2 viral load reduction (VLR) data in all patients receiving bevirimat and in all patients receiving bevirimat > target blood level and without specific Gag changes

Responders*

N Mean VLR

(log10 copies/mL) Responders > 0.5 log10 Responders > 1.0 log10

N (%) VLR N (%) VLR

All Study 203 Patients 44** 0.60 20 (45%) 1.26 15 (34%) 1.42

All Study 203 Patients > Target Blood Level & Without Gag Changes 13 1.26 12

(92%) 1.36 10 (77%) 1.46

*Responders defined as those patients with VL reduction > 0.5 log10

**46 patients received bevirimat; 2 excluded from the efficacy analysis due to pharmacy dosing error

Study 203 was a 14-day functional monotherapy trial in treatment-experienced patients conducted at multiple sites in the US. Five doses were tested: 250, 300, 350, and 400mg of bevirimat liquid and 400mg of bevirimat tablets. Fifty-nine patients were studied, with 46 patients receiving bevirimat and 13 receiving placebo. Forty-four patients were included in the efficacy evaluation, with two excluded due to a pharmacy dosing error. All treatment-related adverse events observed were of mild intensity and of similar type and frequency to placebo. There were no adverse event-related discontinuations and no adverse events required clinical intervention.

For more info: http://srlm.realpennies.com

Sterling Mining Company (OTCBB:SRLM) (March 4th, 2008) was profiled on February 27, 2008 at the Toronto Stock Exchange to celebrate its listing where Ray De Motte and company representatives opened the market in Toronto. The ceremony coincides with the Prospectors and Developers Association of Canada's Annual Convention (PDAC) at which Sterling is an exhibitor (booth 3141) and where over 18,000 delegates are expected to attend.

As part of the listing ceremony, Sterling was featured in an interview with the Canadian news channel CP24, followed by a reception at the TSX with invited guests and members of the Toronto brokerage community. Ray De Motte was also interviewed by BNN on Monday, March 3, 2008. Pictures from the listing ceremony are available at www.sterlingmining.com.

After the successful achievement of its goal to resume production in December 2007, Sterling has set 2008 to be a pivotal year as the Company expects to become an important primary silver producer. With the re-start of the Sunshine mine accomplished, Sterling is expecting to process over 120,000 tons of silver ore in 2008. Sterling's 2007 NI 43-101 technical report forecasts 2.8 million ounces of silver production in 2008.

The Company will report on production milestones as the year progresses along with quarterly operating results.

In 2008, focus at the Sunshine Mine will remain on steadily increasing production from the 2700 and 3100 levels. The Company's mine plan incorporates continuing development of these levels to be followed by rehabilitation and development from the 3700 level to achieve production targets of 250,000 tons per year to maximize mill throughput.

Sterling Mining will continue an aggressive multi-year exploration program targeting both the upper country and lower areas to expand the mine's potential, including under-explored areas of the mine at deeper levels.

Sterling Mining Company now controls over 60,000 acres of silver prospects in Idaho, Montana and Mexico offering additional exploration potential.

Ray De Motte commented: "The Sterling Mining team is focused on aggressively developing the mines' resources and maximizing the value of this operation for our shareholder's benefit. Our production and growth initiatives now underway come at a time of strong silver prices, which are forecasted to remain strong throughout 2008".

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

Sponsored by: http://www.isthemarketopen.com

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com